Kapoor Neeraj, Uchiyama Satoshi, Pill Lucy, Bautista Leslie, Sedra Angie, Yin Lu, Regan Maritoni, Chu Ellen, Rabara Taylor, Wong Melissa, Davey Peter, Fairman Jeff, Nizet Victor
Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070, United States.
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, 9500 Gilman Drive Mail Code 0760, La Jolla, California 92093, United States.
ACS Omega. 2022 Jul 11;7(28):24111-24120. doi: 10.1021/acsomega.1c07360. eCollection 2022 Jul 19.
Surface-expressed bacterial polysaccharides are important vaccine antigens but must be conjugated to a carrier protein for efficient antigen presentation and development of strong memory B cell and antibody responses, especially in young children. The commonly used protein carriers include tetanus toxoid (TT), diphtheria toxoid (DT), and its derivative CRM197, but carrier-induced epitopic suppression and bystander interference may limit the expanded use of the same carriers in the pediatric immunization schedule. Recent efforts to develop a vaccine against the major human pathogen group A (GAS) have sought to combine two promising vaccine antigens-the universally conserved group A cell wall carbohydrate (GAC) with the secreted toxin antigen streptolysin O (SLO) as a protein carrier; however, standard reductive amination procedures appeared to destroy function epitopes of the protein, markedly diminishing functional antibody responses. Here, we couple a cell-free protein synthesis (CFPS) platform, allowing the incorporation of non-natural amino acids into a C-terminally truncated SLO toxoid for the precise conjugation to the polyrhamnose backbone of GAC. The combined immunogen generated functional antibodies against both conserved GAS virulence factors and provided protection against systemic GAS challenges. CFPS may represent a scalable method for generating pathogen-specific carrier proteins for multivalent subunit vaccine development.
表面表达的细菌多糖是重要的疫苗抗原,但必须与载体蛋白偶联,以实现有效的抗原呈递,并引发强烈的记忆B细胞和抗体反应,尤其是在幼儿中。常用的蛋白质载体包括破伤风类毒素(TT)、白喉类毒素(DT)及其衍生物CRM197,但载体诱导的表位抑制和旁观者干扰可能会限制同一载体在儿童免疫计划中的广泛使用。最近,针对主要人类病原体A组链球菌(GAS)开发疫苗的努力试图将两种有前景的疫苗抗原结合起来——普遍保守的A组细胞壁碳水化合物(GAC)与分泌的毒素抗原链球菌溶血素O(SLO)作为蛋白质载体;然而,标准的还原胺化程序似乎破坏了蛋白质的功能表位,显著降低了功能性抗体反应。在这里,我们结合了一个无细胞蛋白质合成(CFPS)平台,允许将非天然氨基酸掺入C末端截短的SLO类毒素中,以便与GAC的聚鼠李糖主链精确偶联。这种组合免疫原产生了针对两种保守的GAS毒力因子的功能性抗体,并提供了针对全身性GAS攻击的保护。CFPS可能代表了一种可扩展的方法,用于为多价亚单位疫苗开发生成病原体特异性载体蛋白。